FAC/FAP belong to the same pathological spectrum and differ from ATTRwt amyloidosis mainly due to ATTR mutations. In this case, ATTRv (amyloid TTR variant) refers to the mutant form of ATTR, and FAC/FAP was renamed to ATTR appended with the specific mutation that caused it (i.e., ATTRV30M) and the accompanying symptom (i.e. ATTR with cardiomyopathy)
[32][22]. Depending on the mutations, the hydrophobic interaction of dimer–dimer formation would vary, resulting in the instability and breakdown of the tetramers. As a result, the tendency to produce the amyloid form is enhanced and favors the development of the disease
[40][30]. FAP was formerly categorized into four types: FAP-I, FAP-II, FAP-III and FAP-IV, and the pathogenicity of FAP and FAC could overlap
[41,42,43][31][32][33]. FAP-I has since been renamed as ATTRV30M amyloidosis and is also known as the Portuguese–Swedish–Japanese type, and haplotype comparison among foci suggested common Portuguese origins among Japanese, Spanish, and Brazilian patients, while Swedish patients had entirely different haplotypic origins
[44,45][34][35]. ATTRV30M amyloidosis resulted in a wide range of symptoms such as sensory-autonomic, gastrointestinal and cardiac disturbances, impotence, and cardiomyopathy; as well as renal insufficiency in later stages of the disease
[46,47][36][37]. A study on 15 Swedish families with ATTRV30M determined through Western blot showed the type of amyloid fibril composition remained the same despite the differences of the disease age of onset. Only one family showed different types of amyloid fibril composition on two brothers with similar ages of disease onset
[48][38]. Despite the endemicity of the early onset form of ATTRV30M in some Portuguese, Japanese, and Swedish populations, the late onset form was shown to be more prevalent in non-endemic areas of Japan and Cyprus than previously thought, and much is still not known about its causative factors
[49,50][39][40]. Symptoms of ATTRI84S amyloidosis were similar to ATTRV30M amyloidosis, but additional sensorimotor polyneuropathy could appear late in the disease
[55][41]. In addition, amyloid deposits could be found in the eye, thyroid, adrenal glands, and blood vessels, leading to additional side effects from both diseases
[56,57,58,59][42][43][44][45]. Even though ATTRv amyloidosis was like ATTRwt amyloidosis in terms of disease pathomechanism, the expression of ATTRv outside cardiac tissue may lead to amyloidosis resulting in hereditary ATTR cardiomyopathy (ATTR-CM). This was described in a Danish family carrying ATTRMet
111 expressed in plasma that led to hereditary ATTR-CM (previously known as familial amyloid cardiomyopathy or FAC), whereas unafflicted members were seronegative
[60][46]. Patients beyond the age of 60 were reported to have hereditary ATTR-CM, and ATTRV122I and ATTRT60A could be responsible. ATTRV122I was most commonly found in 4% of African-Americans, followed by ATTRT60A in patients from United Kingdom and Ireland
[61,62,63][47][48][49]. The role of the non-coding variation of ATTRV122I was assessed in 4,361 unrelated African-Americans. The study showed that this allele increased 6.8-fold the risk of having ten or more outpatient surgeries. Additionally, men had a 15.2-fold higher risk of having ten or more outpatient surgeries. This non-coding variation seemed to accelerate the negative consequences associated with ATTRV122I amyloidosis
[64][50]. Amyloid deposits in cardiac tissues may cause a thickening of cardiac walls leading to congestive heart failure and atrial arrhythmias, and result in cardiac arrest and death
[59,65][45][51]. Carpal tunnel syndrome may manifest in the early phase of ATTRv amyloidosis and may require a great deal of attention and not simply dismissed as an unrelated symptom
[66][52]. More than 140 ATTRv mutations have been identified
[3][53] along with non-amyloidogenic mutations (
Figure 4), which may not produce amyloid, but were reported to cause functional abnormalities
in vivo [67,68][54][55]. Among non-amyloidogenic mutations, few were revealed to have a high affinity for thyroxine
[67][54], and rarely, alanine mutations, particularly A109T and A109V, which were described in a family with dominantly-inherited euthyroid hyperthyroxinemia
[69][56].
Figure 4.
Transthyretin mutation sites and relation to amyloidosis.
4. General Diagnostic Workflow for ATTR Causative Diseases
Upon initial detection of the clinical symptoms mentioned above, additional diagnoses are still required to discern ATTR disease types for prompt treatment. ECG, magnetic resonance imaging (MRI), echocardiography, tissue biopsy, and genetic analysis could be performed for wild-type and hereditary ATTR amyloidoses. ECG is prioritized if the detected symptoms are primarily observed in the heart. In recent years, many kinds of ECG analysis were reported to lead to better initial diagnosis. As an example, left bundle branch block can differentiate ATTRwt amyloidosis from primary light chain amyloidosis (AL) as this ECG pattern can be observed in 40% of ATTRwt patients but is rare (4%) in AL
[70][57]. Notably, low QRS voltages were observed in 60% of AL patients but were not as frequent in ATTRwt patients (40%)
[70,71][57][58]. An abnormal ECG result would call for MRI using gadolinium enhancement by visualizing amyloid deposition in cardiac tissue for a more accurate diagnosis
[72][59]. Echocardiography was used for diagnosing hypoplasia in the left and right ventricles of neonates
[73][60] and has also been considered as an invaluable tool in providing real time and rapid evaluation of ventricular function in neonates and children with suspected ventricular anomalies
[74][61]. This is largely in part due to its noninvasive nature and absence of side effects during right ventricular evaluation
[75][62] which consists of assessment of ventricular atrophy based on ventricular muscle thickness
[76][63]. Echocardiography also proved to be equally valuable in the assessment of left ventricular function through the measurement of different parametric velocities of the ventricular wall
[77][64]. More recently, global longitudinal strain (GLS) measurement through speckle-tracking analysis of 2D-echocardiography was demonstrated to be a feasible non-invasive and more accurate alternative to the more traditional left ventricular ejection fraction (LVEF)
[78][65]. Tissue biopsy could more accurately differentiate whether the disease was due to wild-type or variant-type ATTR deposits compared to simple visualization. If ATTR amyloidosis was suspected following MRI or 2D-echocardiography, tissue should be collected from the appropriate site depending on the patient’s condition, such as the heart tissue and sural nerve
[79][66]. Each tissue was analyzed for ATTR types through amyloid fibril analysis using Congo red, immunohistochemistry, and mass spectrometry
[80,81,82][67][68][69]. Despite its accuracy, acquiring tissue samples internally through biopsy is an invasive procedure when compared to ECG and 2D-echo, thus other more easily accessible organ sources were considered. Not too recently, skin biopsy was shown to be a promising alternative to the otherwise more invasive method of acquiring internal tissues from the heart or sural nerve in ATTRv (FAP) diagnosis
[83][70]. Intraepidermal, sweat gland, and pilomotor nerve fiber densities were measured and compared in ATTRv patients, asymptomatic ATTRv carriers, healthy controls, diabetic neuropathy disease controls, and AL patients
[83][70]. Immunohistochemistry revealed decreased fiber densities from all three tissue sources in ATTRv patients compared to normal controls, while ATTRv carriers showed intermediate reductions. The sensitivity and specificity for ATTRv diagnosis through detecting amyloid in skin was calculated to be 70% and 100%, respectively
[83][70]. Additional genetic analyses using blood can be done to determine the type of disease. ATTR variants were identified by PCR-based full sequence analysis with 99% accuracy
[84,85][71][72]. From these methods, patients with ATTRV112I were diagnosed as ATTR-CM (FAC at the time)
[63][49], and the ATTRV30M variant could suggest amyloid deposition in the cardiac muscle or nerve
[86][73]. If no mutation was found, the patient would be diagnosed with ATTRwt amyloidosis
[30][20].